Should I buy or sell ADC Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ADC Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ADCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADCT, but not buy additional shares or sell existing shares. View ADCT analyst ratings or view top-rated stocks .

What is ADC Therapeutics' stock price target for 2024?

6 equities research analysts have issued 1-year price objectives for ADC Therapeutics' stock. Their ADCT share price targets range from $2.00 to $11.00. On average, they predict the company's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 58.9% from the stock's current price. View analysts price targets for ADCT or view top-rated stocks among Wall Street analysts .

How have ADCT shares performed in 2024?

ADC Therapeutics' stock was trading at $1.66 on January 1st, 2024. Since then, ADCT shares have increased by 184.3% and is now trading at $4.72. View the best growth stocks for 2024 here .

Are investors shorting ADC Therapeutics?

ADC Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 993,100 shares, an increase of 5.7% from the March 15th total of 939,800 shares. Based on an average daily volume of 791,000 shares, the short-interest ratio is presently 1.3 days. Approximately 1.8% of the company's shares are sold short. View ADC Therapeutics' Short Interest .

When is ADC Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our ADCT earnings forecast .

How were ADC Therapeutics' earnings last quarter?

ADC Therapeutics SA (NYSE:ADCT) released its earnings results on Wednesday, March, 13th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.47) by $0.56. The firm earned $16.79 million during the quarter, compared to the consensus estimate of $16.58 million. ADC Therapeutics had a negative net margin of 344.15% and a negative trailing twelve-month return on equity of 1,313.37%.

What other stocks do shareholders of ADC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADC Therapeutics investors own include CVS Health (CVS) , RTX (RTX) , Home Depot (HD) , Procter & Gamble (PG) , Thermo Fisher Scientific (TMO) , Alibaba Group (BABA) , Cisco Systems (CSCO) , Johnson & Johnson (JNJ) and CSX (CSX) .

When did ADC Therapeutics IPO?

ADC Therapeutics (ADCT) raised $126 million in an initial public offering on Friday, May 15th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company served as the underwriters for the IPO.

Who are ADC Therapeutics' major shareholders?

ADC Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.09%).

How do I buy shares of ADC Therapeutics?

Shares of ADCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:ADCT

ADC Therapeutics (ADCT) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free ADCT Stock Alerts

$4.72

-0.04 (-0.84%)

(As of 04/19/2024 ET)

Compare

Today's Range: $4.60
▼
$4.92
50-Day Range: $3.74
▼
$5.30
52-Week Range: $0.36
▼
$6.04

Volume: 646,031 shs
Average Volume: 470,294 shs
Market Capitalization: $390.86 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.50

Get ADC Therapeutics alerts:

ADC Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 58.9% Upside
$7.50 Price Target
Short Interest: Healthy
1.81% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.19
Based on 12 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.20) to ($1.59) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.00 out of 5 stars

Medical Sector

568th out of 911 stocks

Pharmaceutical Preparations Industry

259th out of 418 stocks

3.2

Analyst's Opinion

Consensus Rating
ADC Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 3 buy ratings, 2 hold ratings, and 1 sell rating.
Amount of Analyst Coverage
ADC Therapeutics has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.81% of the float of ADC Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
ADC Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in ADC Therapeutics has recently increased by 5.67%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
ADC Therapeutics does not currently pay a dividend.
Dividend Growth
ADC Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ADCT.

1.8

News and Social Media Coverage

News Sentiment
ADC Therapeutics has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for ADC Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 12 people have searched for ADCT on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added ADC Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ADC Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
35.40% of the stock of ADC Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
41.10% of the stock of ADC Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for ADC Therapeutics are expected to grow in the coming year, from ($2.20) to ($1.59) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ADC Therapeutics is -1.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ADC Therapeutics is -1.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About ADC Therapeutics Stock (NYSE:ADCT)

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

ADCT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ADCT Stock News Headlines

April 19, 2024 | americanbankingnews.com

Analysts Set Expectations for ADC Therapeutics SA's Q1 2024 Earnings (NYSE:ADCT)

April 18, 2024 | americanbankingnews.com

ADC Therapeutics SA (NYSE:ADCT) Short Interest Up 5.7% in March

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 16, 2024 | markets.businessinsider.com

Buy Rating Affirmed for ADC Therapeutics on Strong Preclinical Data and Promising Trial Progress

April 16, 2024 | americanbankingnews.com

ADC Therapeutics' (ADCT) "Buy" Rating Reaffirmed at HC Wainwright

April 4, 2024 | msn.com

ADC Therapeutics gains after data for lymphoma therapy

April 4, 2024 | globenewswire.com

ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

April 3, 2024 | globenewswire.com

ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 1, 2024 | finance.yahoo.com

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

March 16, 2024 | finance.yahoo.com

US$10.00 - That's What Analysts Think ADC Therapeutics SA (NYSE:ADCT) Is Worth After These Results

March 15, 2024 | seekingalpha.com

ADC Therapeutics SA (ADCT) Q4 2023 Earnings Call Transcript

March 14, 2024 | finance.yahoo.com

Q4 2023 ADC Therapeutics SA Earnings Call

March 13, 2024 | finance.yahoo.com

ADC Therapeutics SA (ADCT) Reports Mixed 2023 Financial Results Amid Strategic Reset

March 13, 2024 | globenewswire.com

ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

March 6, 2024 | globenewswire.com

ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit

March 6, 2024 | globenewswire.com

ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024

March 5, 2024 | globenewswire.com

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting

February 27, 2024 | finanznachrichten.de

ADC Therapeutics SA: ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

February 27, 2024 | globenewswire.com

ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

February 24, 2024 | msn.com

ADC Therapeutics (ADCT) Price Target Increased by 9.38% to 8.93

February 23, 2024 | benzinga.com

ADC Therapeutics Stock (NYSE:ADCT), Quotes and News Summary

February 21, 2024 | finance.yahoo.com

Earnings Preview: Cytek Biosciences, Inc. (CTKB) Q4 Earnings Expected to Decline

February 20, 2024 | finance.yahoo.com

Earnings Preview: ADC Therapeutics SA (ADCT) Q4 Earnings Expected to Decline

February 15, 2024 | msn.com

The 3 Biotech Stocks That Could Make Your February Unforgettable

February 15, 2024 | investorplace.com

The 3 Biotech Stocks That Could Make Your February Unforgettable

February 8, 2024 | msn.com

The 3 Most Undervalued Biotech Stocks to Buy in February 2024

See More Headlines

Receive ADCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ADC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/13/2024
Today: 4/20/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NYSE:ADCT
CUSIP: N/A
CIK: 1771910
Web: www.adctherapeutics.com
Phone: 41-21-653-0200
Fax: N/A
Employees: 273
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.50
High Stock Price Target: $11.00
Low Stock Price Target: $2.00
Potential Upside/Downside: +58.9%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.93)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-240,050,000.00
Net Margins: -344.15%
Pretax Margin: -280.94%
Return on Equity: -1,313.37%
Return on Assets: -53.29%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.97
Quick Ratio: 4.73

Sales & Book Value

Annual Sales: $69.56 million
Price / Sales: 5.62
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.93) per share
Price / Book: -2.45

Miscellaneous

Outstanding Shares: 82,810,000
Free Float: 53,314,000
Market Cap: $390.86 million
Optionable: Optionable
Beta: 1.73

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Dr. Ameet Mallik M.B.A. (Age 51)
M.S., CEO & Director
Comp: $1.84M
Mr. Jose I. Carmona M.B.A. (Age 52)
Chief Financial Officer
Comp: $884.86k
Dr. Mohamed Zaki M.D. (Age 59)
Ph.D., Chief Medical Officer
Comp: $2.41M
Ms. Lisa Michelle Kallebo
Corporate Controller & Chief Accounting Officer
Dr. Michael Mulkerrin Ph.D. (Age 69)
Chief Technical Operations Officer
Dr. Patrick van Berkel Ph.D. (Age 56)
Chief Scientific Officer
Amanda Hamilton
Investor Relations Officer
Mr. Peter J. Graham Esq. (Age 57)
Chief Legal Officer
Ms. Eugenia Litz
Vice President of Investor Relations & Corporate Communications
Ms. Kimberly Pope (Age 57)
Senior VP & Chief People Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ADCT Stock Analysis - Frequently Asked Questions

Should I buy or sell ADC Therapeutics stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ADC Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ADCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADCT, but not buy additional shares or sell existing shares.
View ADCT analyst ratings or view top-rated stocks.
What is ADC Therapeutics' stock price target for 2024?: 6 equities research analysts have issued 1-year price objectives for ADC Therapeutics' stock. Their ADCT share price targets range from $2.00 to $11.00. On average, they predict the company's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 58.9% from the stock's current price.
View analysts price targets for ADCT or view top-rated stocks among Wall Street analysts.
How have ADCT shares performed in 2024?: ADC Therapeutics' stock was trading at $1.66 on January 1st, 2024. Since then, ADCT shares have increased by 184.3% and is now trading at $4.72.
View the best growth stocks for 2024 here.
Are investors shorting ADC Therapeutics?: ADC Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 993,100 shares, an increase of 5.7% from the March 15th total of 939,800 shares. Based on an average daily volume of 791,000 shares, the short-interest ratio is presently 1.3 days. Approximately 1.8% of the company's shares are sold short.
View ADC Therapeutics' Short Interest.
When is ADC Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ADCT earnings forecast.
How were ADC Therapeutics' earnings last quarter?: ADC Therapeutics SA (NYSE:ADCT) released its earnings results on Wednesday, March, 13th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.47) by $0.56. The firm earned $16.79 million during the quarter, compared to the consensus estimate of $16.58 million. ADC Therapeutics had a negative net margin of 344.15% and a negative trailing twelve-month return on equity of 1,313.37%.

What other stocks do shareholders of ADC Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ADC Therapeutics investors own include CVS Health (CVS), RTX (RTX), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Alibaba Group (BABA), Cisco Systems (CSCO), Johnson & Johnson (JNJ) and CSX (CSX).
When did ADC Therapeutics IPO?: ADC Therapeutics (ADCT) raised $126 million in an initial public offering on Friday, May 15th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company served as the underwriters for the IPO.
Who are ADC Therapeutics' major shareholders?: ADC Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.09%).
How do I buy shares of ADC Therapeutics?: Shares of ADCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ADCT) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial